In vitro Evidence That Combination Therapy With CD16-Bearing NK-92 Cells and FDA-Approved Alefacept Can Selectively Target the Latent HIV Reservoir in CD4+ CD2hi Memory T Cells

In vitro Evidence That Combination Therapy With CD16-Bearing NK-92 Cells and FDA-Approved Alefacept Can Selectively Target the Latent HIV Reservoir in CD4+ CD2hi Memory T Cells

Elimination of the latent HIV reservoir remains the biggest hurdle to achieve HIV cure. In order to specifically eliminate HIV infected cells they must be distinguishable from uninfected cells. CD2 was recently identified as a potential marker enriched in the HIV-1 reservoir on CD4+ T cells, the lar...

Full description

Bibliographic Details
Main Authors: Amanda G. Tomalka, Ivelisse Resto-Garay, Kerry S. Campbell, Daniel L. Popkin
Format: Article
Language:English
Published: Frontiers Media S.A. 2018-11-01
Series:Frontiers in Immunology
Subjects:
HIV
ADCC
alefacept
NK
NK92
FDA
Online Access:https://www.frontiersin.org/article/10.3389/fimmu.2018.02552/full

Internet

https://www.frontiersin.org/article/10.3389/fimmu.2018.02552/full

Similar Items